14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients with HCV genotype 2 or 3 infection who have a rapid virological response to treatment are randomised to either 14 or 24 weeks HCV treatment. Our hypothesis is that there is no important difference in effect between the two treatment effect.
| Condition | Intervention | Phase |
|---|---|---|
|
Hepatitis C Virus Infection |
Drug: Pegylated Interferon alfa 2b and ribavirin |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | 14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response |
- Sustained virological response (SVR) =HCV RNA negativity (<20 IU/ml) six months after end of treatment.
- Change in health related quality as measured by short from 36 (SF-36) from baseline to 6 months after end of treatment.
- Sick leave in patients treated for 14 or 24 weeks treatment
| Estimated Enrollment: | 435 |
| Study Start Date: | March 2004 |
| Estimated Study Completion Date: | September 2006 |
Patients with HCV genotype 2 or 3 infection are currently recommended 6 months treatment with pegylated interferon alfa (2a or 2b) and ribavirin.Approximately 80% obtain sustained virological response (HCV RNA undetectable 6 months after treatment) to this approach. However, the treatment is associated with many and sometimes serious side effects. In addition, the treatment is costly also in econimical terms. Increasing the treatment duration beyond 6 months does not increase the response rate. Shorter treatment has only been assessed in small trials, but the results have been encouraging.
In this randomised, open label,multicenter phase 3 trial with acitive controls patients are treated with pegylated interferon alfa 2a (PegIntron (R), Schering Plough NJ)(1,5 mcg/kg)and ribavirin (Rebetol (R), Schering Plough, NJ) (800-1400mg based on weight)for 4 weeks. Those who are HCV RNA negative at week 4 (<50 IU; Cobas Amplicor Monitor Test, Roche Diagnostic) are defined as rapid virological responders and randomised to either an additional 10 or 20 weeks combination treatment. Patients who are HCV RNA positive are all treated for 20 more weeks. The endpoint is sustained virological response defined as undetectable HCV RNA 24 weeks after end of treatment.
Our hypothesis is that there is no important difference in the effect in the two groups.
This is a non-inferiority trial. The smallest difference considered to be clinically important is 10%. Thus to state "non-inferiority" the 95% confidence interval of the observed difference between the groups shall not overlap 10%. Both intention to treat and and per protocol analyses will be published. Conclusion will be conservative and based on the analysis who detect the biggest difference.
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
HCV RNA positive Genotype 2 or 3 Treatment naive Raised ALT
-
Exclusion Criteria:
Active substance abuse Poorly controlled psychiatric disease Decompensated cirrhosis HBsAg positive Anti-HIV positive Suffering from other significant concurrent medical conditions including chronic liver diseases -
Contacts and Locations| Norway | |
| Ullevaal University Hospital | |
| Oslo, Norway, 0407 | |
| Principal Investigator: | Olav Dalgard, MD PhD | Ullevaal University Hospital, Oslo, Norway |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00308048 History of Changes |
| Other Study ID Numbers: | P03720 |
| Study First Received: | March 27, 2006 |
| Last Updated: | July 3, 2011 |
| Health Authority: | Norway: Norwegian Medicines Agency |
Keywords provided by Oslo University Hospital:
|
Interferon Pegylated interferon Pegylated interferon alfa 2b Hepatitis C Genotype 2 Genotype 3 |
Rapid virological response Short treatment 14 weeks treatment health related quality of life sick leave Injecting drug use |
Additional relevant MeSH terms:
|
Hepatitis Hepatitis A Hepatitis C Virus Diseases Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Enterovirus Infections Picornaviridae Infections RNA Virus Infections Flaviviridae Infections Interferon-alpha Interferon Alfa-2a Interferon Alfa-2b Interferons |
Ribavirin Peginterferon alfa-2b Reaferon Antiviral Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Immunologic Factors Physiological Effects of Drugs Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Growth Inhibitors Antineoplastic Agents Adjuvants, Immunologic |
ClinicalTrials.gov processed this record on May 16, 2013